Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
71,366,920
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
52,538,995
-
Shares change
-
-2,051,548
-
Total reported value, excl. options
-
$116,636,299
-
Value change
-
-$3,488,602
-
Put/Call ratio
-
56%
-
Number of buys
-
47
-
Number of sells
-
63
-
Price
-
$2.22
Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q3 2025
As of 30 Sep 2025 C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) had 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 52,538,995 shares of stock of the company.
Largest 10 holders included Lynx1 Capital Management LP, Soleus Capital Management, L.P., ORBIMED ADVISORS LLC, MORGAN STANLEY, WASATCH ADVISORS LP, VANGUARD GROUP INC, BANK OF AMERICA CORP /DE/, MILLENNIUM MANAGEMENT LLC, SILVERARC CAPITAL MANAGEMENT, LLC, and BlackRock, Inc..
This table shows 96 institutional shareholders of the security as of 30 Sep 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.